Haesook T Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9522025/publications.pdf

Version: 2024-02-01

111 papers	6,723 citations	126907 33 h-index	62596 80 g-index
112 all docs	112 docs citations	112 times ranked	8776 citing authors

#	Article	IF	Citations
1	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. New England Journal of Medicine, 2011, 365, 2055-2066.	27.0	996
2	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood, 2014, 123, 3664-3671.	1.4	730
3	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood, 2005, 106, 2903-2911.	1.4	430
4	Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis. Clinical Cancer Research, 2007, 13, 559-565.	7.0	421
5	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. Science Translational Medicine, 2013, 5, 179ra43.	12.4	401
6	A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood, 2012, 120, 905-913.	1.4	310
7	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood, 2016, 128, 195-203.	1.4	259
8	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Antiâ€“T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Diseaseâ€“Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 4003-4011.	1.6	258
9	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation, 2010, 120, 1479-1493.	8.2	212
10	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 2017, 129, 1380-1388.	1.4	209
11	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood, 2016, 128, 130-137.	1.4	176
12	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	1.4	156
13	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood, 2016, 127, 646-657.	1.4	145
14	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight, 2016, 1, e89278.	5.0	126
15	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1â€“1b study. Lancet Haematology,the, 2019, 6, e38-e47.	4.6	98
16	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood, 2016, 127, 2489-2497.	1.4	92
17	Gene expressionâ€“based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 2016, 128, 1845-1853.	1.4	83
18	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. Journal of Clinical Oncology, 2022, 40, 189-201.	1.6	79

#	Article	IF	Citations
19	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research, 2017, 23, 735-745.	7.0	74
20	Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, 1248-1251.	2.0	64
21	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood, 2020, 135, 2182-2191.	1.4	62
22	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2019, 6, e419-e428.	4.6	60
23	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 352-364.	5.2	58
24	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. Biology of Blood and Marrow Transplantation, 2015, 21, 873-880.	2.0	56
25	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. Journal of Clinical Investigation, 2020, 130, 4624-4636.	8.2	55
26	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. Haematologica, 2016, 101, 1260-1266.	3.5	54
27	The addition of sirolimus to the graftâ€versusâ€host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. British Journal of Haematology, 2016, 173, 96-104.	2.5	53
28	Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 1516-1521.	2.0	50
29	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1737-1743.	2.0	48
30	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. Journal of Clinical Investigation, 2022, 132, .	8.2	48
31	Nextâ€generation sequencingâ€based detection of circulating tumour <scp>DNA</scp> After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology, 2016, 175, 841-850.	2.5	47
32	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 668-675.	2.0	45
33	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances, 2019, 3, 2550-2561.	5.2	44
34	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2344-2353.	2.0	37
35	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica, 2017, 102, 1185-1191.	3.5	31
36	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood, 2018, 131, 2836-2845.	1.4	30

#	Article	IF	Citations
37	High Î”Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. Blood, 2015, 126, 2302-2306.	1.4	28
38	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica, 2016, 101, 1251-1259.	3.5	27
39	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica, 2015, 100, 1222-1227.	3.5	24
40	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Advances, 2019, 3, 984-994.	5.2	24
41	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1733-1740.	2.0	23
42	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances, 2019, 3, 1167-1174.	5.2	23
43	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances, 2021, 5, 861-871.	5.2	23
44	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	5.2	22
45	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS ONE, 2015, 10, e0132564.	2.5	22
46	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Advances, 2021, 5, 5140-5149.	5.2	21
47	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. Blood, 2015, 126, 497-497.	1.4	21
48	White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. American Journal of Hematology, 2014, 89, 591-597.	4.1	19
49	<scp>MYD</scp>88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in <scp>CLL</scp>. British Journal of Haematology, 2019, 184, 925-936.	2.5	18
50	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 2216-2223.	2.0	18
51	Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom. Biology of Blood and Marrow Transplantation, 2013, 19, 860-866.	2.0	17
52	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood, 2017, 130, 2889-2899.	1.4	17
53	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 2084-2091.	2.0	16
54	BK virusâ€“specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	5.2	16

#	Article	IF	Citations
55	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1499-1508.	3.5	15
56	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	2.0	15
57	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 1006-1012.	2.4	15
58	Allogeneic hematopoietic cell transplantation outcomes in patients with Richterâ€™s transformation. Haematologica, 2021, 106, 3219-3222.	3.5	15
59	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood, 2016, 128, 3243-3243.	1.4	15
60	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). Blood, 2016, 128, 505-505.	1.4	12
61	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	5.2	12
62	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. Clinical Cancer Research, 2015, 21, 1010-1018.	7.0	11
63	KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation,. Blood, 2011, 118, 4150-4150.	1.4	11
64	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
65	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clinical Immunology, 2019, 207, 18-23.	3.2	10
66	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood, 2018, 132, 705-705.	1.4	10
67	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. Blood, 2016, 128, 641-641.	1.4	10
68	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. Blood, 2015, 126, 4158-4158.	1.4	9
69	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 650-657.	1.2	6
70	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 972-972.	1.4	6
71	Safety and Efficacy of Allogeneic Hematopoetic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. Blood, 2015, 126, 2018-2018.	1.4	5
72	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 860-860.	1.4	5

#	Article	IF	Citations
73	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. Blood, 2012, 120, 3069-3069.	1.4	5
74	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2017, 23, 103-112.	2.0	4
75	Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. Leukemia and Lymphoma, 2018, 59, 1986-1989.	1.3	4
76	A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation.. Blood, 2008, 112, 1158-1158.	1.4	4
77	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. Blood, 2016, 128, 667-667.	1.4	4
78	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 1312-1315.	1.3	3
79	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 835-835.	1.4	3
80	The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. Blood, 2013, 122, 704-704.	1.4	3
81	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. Blood, 2015, 126, 522-522.	1.4	3
82	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. Blood, 2016, 128, 508-508.	1.4	3
83	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. Blood, 2021, 138, 264-264.	1.4	3
84	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3156-3156.	1.4	2
85	Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica, 2022, 107, 2617-2629.	3.5	2
86	Response to Helsby and Tingle. American Journal of Hematology, 2011, 86, 384-384.	4.1	1
87	Reply to induction therapy and outcome in acute myeloid leukemia. Cancer, 2011, 117, 2237-2237.	4.1	1
88	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). Blood, 2018, 132, 2110-2110.	1.4	1
89	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 3680-3680.	1.4	1
90	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. Blood, 2007, 110, 166-166.	1.4	1

#	Article	IF	Citations
91	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. Blood, 2008, 112, 2310-2310.	1.4	1
92	GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies. Blood, 2008, 112, 825-825.	1.4	1
93	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. Blood, 2015, 126, 2022-2022.	1.4	1
94	Comprehensive Genetic Characterization of 17p Deleted CLL Identifies Predictors of Overall Survival. Blood, 2015, 126, 2907-2907.	1.4	1
95	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. Blood, 2015, 126, 4159-4159.	1.4	1
96	Engraftment Syndrome After Allogeneic Hematopoietic Cell Transplantation: Relationship to Acute Gvhd and Impact on Transplant Outcomes. Blood, 2011, 118, 3013-3013.	1.4	1
97	Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RARÎ²2) Gene Promoter.. Blood, 2004, 104, 1124-1124.	1.4	0
98	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. Blood, 2005, 106, 894-894.	1.4	0
99	IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.. Blood, 2005, 106, 1257-1257.	1.4	0
100	Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid Disorders. Blood, 2010, 116, 1325-1325.	1.4	0
101	Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome. Blood, 2010, 116, 1323-1323.	1.4	0
102	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	1.4	0
103	A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease. Blood, 2012, 120, 744-744.	1.4	0
104	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	1.4	0
105	Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. Blood, 2014, 124, 662-662.	1.4	0
106	Immunosuppression Taper to Induce Graft-Verus-Tumor Activity As the Sole Therapy for Early Relapse after Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2014, 124, 2504-2504.	1.4	0
107	MYD88 L265P Mutations Influence Clinical Outcome and Identify a Pathway for Targeted Inhibition in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 491-491.	1.4	0
108	Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease. Blood, 2015, 126, 3133-3133.	1.4	0

#	Article	IF	Citations
109	Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 742-742.	1.4	0
110	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3425-3425.	1.4	0
111	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 3376-3376.	1.4	0